E7389 in Treating Patients With Advanced Solid Tumors

NCT00047034 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

31

Enrollment

NIH

Sponsor class

Conditions

Unspecified Adult Solid Tumor, Protocol Specific

Interventions

DRUG: eribulin mesylate
OTHER: pharmacological study
OTHER: laboratory biomarker analysis

Sponsor

National Cancer Institute (NCI)